Utah Med Prods Stock Price, News & Analysis

Utah Medical Products (Nasdaq: UTMD) reported a mixed financial performance for Q3 2022, with revenues rising 3% year-over-year, while gross profit and operating income saw modest increases of 1%. Net income rose by 2%, reflecting ongoing challenges like supply chain disruptions and litigation costs, as well as the impact of a stronger USD on foreign sales. Despite these hurdles, management highlighted better-than-expected results and maintained a solid cash position of $69.5 million, alongside a commitment to stock repurchases and dividends, indicating continued shareholder value focus.

Utah Medical Products (NASDAQ:UTMD) declares a quarterly cash dividend of $0.29 per share, payable on October 5, 2022, to shareholders on record by September 16, 2022. This dividend reflects a 1.8% increase compared to the same quarter last year. Utah Medical Products specializes in developing and manufacturing medical devices for women and infants, recognized globally for quality and performance.

UTMD reported strong financial results for Q2 and H1 2022, exceeding initial projections. Revenues grew by 7% in Q2 and 9% in H1 compared to 2021, while net income surged by 19.7% in Q2 and 18% in H1. Despite rising variable costs impacting profit margins, operating income increased by 6% in Q2 and 10.7% in H1. The company maintained a robust balance sheet with no debt, and cash and investments rose to $66.2 million. The share price ended Q2 at $85.90, reflecting a 14.1% decline from the end of 2021, partly due to external market pressures.

Utah Medical Products (NASDAQ:UTMD) has announced a quarterly cash dividend of $.29 per share, payable on July 6, 2022, to shareholders of record by June 17, 2022. This reflects a 1.8% increase over the previous year's dividend. The company focuses on developing and marketing specialty medical devices for women and their babies, recognized for optimal long-term outcomes globally.

In the first quarter of 2022, Utah Medical Products (UTMD) reported revenues of $12.3 million, a 12.4% increase from 1Q 2021. Gross profit rose 8.4% to $7.5 million, while operating income climbed 16.3% to $4.5 million. Net income increased 16.9% to $3.5 million, with earnings per share (EPS) rising 16.6% to $0.964. While domestic sales grew 18%, international sales rose 4%. However, gross profit margin decreased to 61.1% due to higher costs. Cash and investments improved to $65.9 million, indicating a strong financial position.

Utah Medical Products (NASDAQ:UTMD) announced a quarterly cash dividend of $.29 per share, reflecting a 1.8% increase from the previous year. The dividend will be payable on April 5, 2022, to shareholders of record as of March 18, 2022. The company is recognized for its development and marketing of specialty medical devices, particularly focused on women's health and pediatric care, serving clinicians in over a hundred countries. For further details, visit www.utahmed.com.

Utah Medical Products (Nasdaq: UTMD) announced its 4Q 2021 financial results, showing substantial recovery from the pandemic impact. Key figures include a 21% increase in net income and earnings per share, both compared to 4Q 2020. Annual revenues rose by 16%, with gross profits up 21%. The company maintained a solid financial position, ending 2021 with $61 million in cash and a special $2.00/share dividend paid to stockholders. Despite challenges such as inflation and supply chain issues, UTMD's operational efficiency improved, demonstrating strong resilience and profitability.

Utah Medical Products, Inc. (NASDAQ:UTMD) announced a special cash dividend of $2.00 per share, payable on December 29, 2021, to stockholders of record by December 15, 2021. This action replaces the normal quarterly dividend and aims to maximize returns for shareholders. The company reported a cash balance of $64.3 million as of September 30, 2021, despite distributing $3.1 million in dividends earlier this year. Chairman Kevin Cornwell highlighted that this dividend reflects ongoing excellent operating performance and strategic cash management.

Utah Medical Products (Nasdaq: UTMD) reported robust 3Q 2021 financial results, showing a recovery from pandemic-induced dips. Revenues increased by 20% compared to 3Q 2020, with net income rising by 43% to $4,206. Furthermore, 9M 2021 results surpassed 2020, with a 44% rise in net income and earnings per share increased to $2.915. Cost management and a weaker USD further contributed to profitability, with gross profit margins at 64.2%. Notably, cash reserves grew to $64.3 million, reflecting strong operational performance in the medical device sector.